| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(9 years from now) | |
| US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(16 years from now) | |
Scemblix is owned by Novartis.
Scemblix contains Asciminib Hydrochloride.
Scemblix has a total of 2 drug patents out of which 0 drug patents have expired.
Scemblix was authorised for market use on 29 October, 2021.
Scemblix is available in tablet;oral dosage forms.
Scemblix can be used as treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml).
Drug patent challenges can be filed against Scemblix from 29 October, 2025.
The generics of Scemblix are possible to be released after 14 May, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2026 |
| Orphan Drug Exclusivity(ODE-382) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-381) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 29 October, 2025
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: TABLET;ORAL
SCEMBLIX family patents
